ADAM17
Top View
- Converting Enzyme (TACE&Sol;ADAM17)
- A Systematic Study of Modulation of ADAM-Mediated Ectodomain Shedding by Site-Specific O-Glycosylation
- The Role of the Metalloproteases ADAM8, 9, 10 and 17 in Leukocyte Migration in Vitro
- ADAM17 Is a Tumor Promoter and Therapeutic Target in Western Diet
- Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation
- ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy in Vitro
- Analysis of the Conditions That Affect the Selective Processing of Endogenous Notch1 by ADAM10 and ADAM17
- Chemotherapy-Induced Activation of ADAM-17: a Novel Mechanism of Drug Resistance in Colorectal Cancer
- To Measure ADAM10 and ADAM17 Sheddase Activities in Cell and Tissue Lysates
- Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer
- Regulated ADAM17-Dependent EGF Family Ligand Release by Substrate-Selecting Signaling Pathways
- Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators
- ADAM17 Limits the Expression of CSF1R on Murine Hematopoietic Progenitors Amy M
- Endothelial Cell Malignancies: New Insights from the Laboratory and Clinic
- Characterization of NUMB As a Regulator of Anaplastic Lymphoma Kinase
- Insulin Treatment Attenuates Renal ADAM17 and ACE2 Shedding in Akita Diabetic Mice
- ADAM17: an Emerging Therapeutic Target for Lung Cancer
- Acute Myeloid Leukemia Targets for Bispecific Antibodies